[
  {
    "ts": null,
    "headline": "Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.",
    "summary": "A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.",
    "url": "https://finnhub.io/api/news?id=ec6b84b673d39f1e4600d814b13960f4d557f79639884661936bf748ab16fce4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752404460,
      "headline": "Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.",
      "id": 135911252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.",
      "url": "https://finnhub.io/api/news?id=ec6b84b673d39f1e4600d814b13960f4d557f79639884661936bf748ab16fce4"
    }
  },
  {
    "ts": null,
    "headline": "Why Novartis Is Still A 'Buy' After 15% Surge",
    "summary": "Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks. Find out why NVS stock is a buy.",
    "url": "https://finnhub.io/api/news?id=ed6b3e9c41c0c4097ff67891dd2e8c7caf7cf443c0fb78ffe110c1c84137ab35",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752403500,
      "headline": "Why Novartis Is Still A 'Buy' After 15% Surge",
      "id": 135910850,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1644466793/image_1644466793.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks. Find out why NVS stock is a buy.",
      "url": "https://finnhub.io/api/news?id=ed6b3e9c41c0c4097ff67891dd2e8c7caf7cf443c0fb78ffe110c1c84137ab35"
    }
  }
]